Home
Search Center
Journal List
CMA
Contact US
|
Chinese
You Position:
Home
> Paper
Reference intervals for steroid hormones in healthy 6-to 15-year-old girls based on liquid chromatography-tandem mass spectrometry in China
( views:0, downloads:0 )
Author:
No author available
Journal Title:
Chinese Medical Journal
Issue:
10
DOI:
10.1097/CM9.0000000000000771
Key Word:
No keyword available
Abstract: No abstract available
Reference
[1]Xiao-Ling Cai,Li-Nong Ji.
Treatment response between Asian and non-Asian patients with type 2 diabetes: is there any similarity or difference?
[J].2019,(1).
[2]Rawshani, Aidin,Rawshani, Araz,Franzen, Stefan,etc.
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
[J].2018,379(7).
[3]Francesco,Cosentino,Peter J,Grant,Victor,Aboyans,etc.
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
[J].2020,41(2).
[4]McAllister, David A.,Read, Stephanie H.,Kerssens, Jan,etc.
Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus
[J].2018,138(24).
[5]Bernard, Zinman,Christoph, Wanner,John M, Lachin,etc.
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
[J].2015,373.
[6]Khan,H.,Kalogeropoulos,A.P.,Zannad,F.,etc.
Incident heart failure in relation to vascular disease: Insights from the Health, Aging, and Body Composition Study
[J].2014,16(5).
[7]Wiviott, S. D.,Raz, I.,Bonaca, M. P.,etc.
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
[J].2019,380(4).
[8]McMurray, John J., V,DeMets, David L.,Inzucchi, Silvio E.,etc.
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
[J].2019,21(5).
[9]Neal, Bruce,Perkovic, Vlado,Mahaffey, Kenneth W.,etc.
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
[J].2017,377(7).
[10]Paulus,W.J.,Tsch?pe,C..
A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
[J].2013,62(4).
[11]Perkovic, V.,Jardine, M. J.,Neal, B.,etc.
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
[J].2019,380(24).
[12].
Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1·9 million people
[J].2015,3(2).
[13]Marx, Nikolaus,McGuire, Darren K..
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
[J].2016,37(42).
[14]Cooper Lauren B.,Yap Jonathan,Tay Wan Ting,etc.
Multi‐ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF‐ACTION trial and the ASIAN‐HF registry
[J].2018,20(9).
[15]Frank R, Heinzel,Felix, Hohendanner,Ge, Jin,etc.
Myocardial hypertrophy and its role in heart failure with preserved ejection fraction.
[J].2015,119.
[16]Jacob A, Udell,Matthew A, Cavender,Deepak L, Bhatt,etc.
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials.
[J].2015,3(5).
WanfangData CO.,Ltd All Rights Reserved
About WanfangData
|
Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:
yiyao@wanfangdata.com.cn